YMC Completes Phase 1 of Growth Plan in America
YMC America has completed the successful co-location and expansion of its US business operations at its growing campus in Devens, MA. The purpose of the move was to consolidate operations in a single facilities center, while also adding much-needed expansion of resources, space, and laboratories. Read more at link.
Previous Article
YMC 5 Year Vision Related Posts
September 4, 2026
YMC America Brings U.S.-Supplied ASME U-Stamped DAC Columns to Pharmaceutical Manufacturers
YMC America will be the First U.S.-Based Supplier of ASME U-Stamped DAC Columns.
The company’s DAC columns support pharmaceutical and biopharmaceutical customers from process development through commercial production. Systems are used in laboratory, pilot, and production-scale chromatography applications, including purification processes for peptides, oligonucleotides, and small-molecule APIs.
September 9, 2026
Tecnologias Analíticas para Peptídeos Terapêuticos- Portuguese
Os peptídeos terapêuticos são uma classe emergente de insumos farmacêuticos ativos que, juntamente com outras classes de bioprodutos, vêm despertando grande interesse devido às suas vantagens únicas.
September 9, 2026
Tecnologías Analíticas para Péptidos Terapéuticos- Spanish
El primer péptido estudiado en este campo fue la insulina, una cadena de 51 aminoácidos que fue aislada originalmente en 1921 por Frederick Banting y Charles Best y que posteriormente se convirtió en el primer péptido disponible comercialmente (1923). Actualmente, existe una extensa lista de péptidos disponibles comercialmente en el mercado, incluidos los conocidos análogos de GLP-1, como liraglutida, semaglutida y tirzepatida.
